Perm Medical Journal,
Journal Year:
2024,
Volume and Issue:
41(6), P. 92 - 108
Published: Dec. 15, 2024
To
determine
contemporary
prospects
for
the
use
of
non-glycemic
effects
sodium-glucose
cotransporter-2
inhibitors
in
comorbid
patients,
analysis
existing
studies
was
carried
out.
The
mechanisms
action
discovered
during
EMPA-REG
OUTCOME
study
which
were
previously
unknown,
encouraged
further
research
on
these
drugs
other
pathological
conditions.
authors
article
have
analyzed
some
clinical
and
preclinical
this
drug
group
such
conditions
as
stroke,
cancer,
rheumatological
diseases,
rhythm
disorders,
well
their
impact
development
major
adverse
cardiovascular
events.
oxidative
stress
suppression
myocardium
nervous
tissue
with
an
increase
number
mitochondria
reduces
risk
developing
improves
neoangiogenesis
focus
ischemic
necrosis,
has
neuroprotective
are
described
article.
In
oncological
gliflozins
prevent
proliferation
tumor
cells
oncogenesis
through
induction
late
apoptosis
also
cardioprotective
patients
undergoing
chemotherapy.
medicines
incidence
events,
restenosis
after
intravascular
interventions.
positive
effect
course
diseases
improving
laboratory
parameters
a
reducing
frequency
exacerbations
visits
to
doctor
gout.
With
constant
conditions,
it
is
important
carry
out
pleiotropic
subsequent
introduction
new
data
into
practice.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(12), P. 2797 - 2797
Published: Dec. 10, 2024
Background:
SGLT-2
inhibitors
(SGLT-2i)
and
GLP-1
receptor
agonists
(GLP-1RA)
have
demonstrated
nephro-
cardioprotective
effects,
but
their
neuroprotective
properties,
especially
concerning
stroke
severity,
mechanisms
are
not
unambiguous.
We
aimed
to
study
the
influence
of
SGLT-2i
with
different
selectivity
GLP-1RA
on
brain
damage
volume
neurological
status
in
non-diabetic
diabetic
rats
investigate
underlying
mechanisms.
Methods:
Non-diabetic
Wistar
were
divided
into
five
groups
(n
=
10
each)
received
empagliflozin,
canagliflozin,
or
dulaglutide
as
drugs
metformin
comparison
drug.
Control
animals
administered
0.9%
NaCl
for
7
days
before
stroke.
At
48
h
after
stroke,
we
assessed
deficit,
neuronal
astroglial
markers,
volume.
also
modeled
type
2
DM
using
high-fat
diet+nicotinamide/streptozotocin
method
established
similar
treatment
groups.
After
8
weeks,
subjected
further
neuroglial
necrosis
measurement.
Results:
In
rats,
all
showed
an
infarct-limiting
effect;
more
effective
than
metformin.
DULA
improved
compared
MET
treatment.
All
decreased
neurofilament
light
chains
(NLCs)
level
none
them
glial
marker
S100BB.
DM,
similarly,
had
effects.
Neurological
deficit
was
most
pronounced
untreated
reduced
by
drugs.
NLC
level;
None
affected
neuron-specific
enolase.
Conclusions:
experimental
might
be
conditions
it
influences
both
status.
decrease
damage,
while
highly
selective
EMPA,
low-selective
CANA,
impact
neuroglia
conditions.
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 19, 2024
Abstract
Synchronized
neurogenesis
and
angiogenesis
after
stroke
have
been
well
documented,
inducing
neurovascular
remodeling
may
provide
a
promising
strategy
to
promote
tissue
repair
functional
recovery.
Dl-3-n-butylphthalide
(NBP)
was
reported
exert
potent
angiogenic
activity
in
rodent
models
of
stroke.
However,
little
is
currently
known
regarding
the
effects
mechanisms
NBP
on
ischemic
This
study
determine
whether
how
promoted
cerebral
injury.
Adult
C57BL/6
mice,
subjected
occlusion
distal
branches
middle
artery
(dMCAO),
were
treated
with
NBP.
The
efficacy
assessed
using
neurologic
deficits
infarct
volume.
Immunofluorescent
staining
applied
evaluate
neurogenesis.
regulation
Wnt/β-catenin
signaling
pathway
neurotrophic
factors
detected
by
western
blotting
qRT-PCR.
Administration
reduced
volume
ameliorated
neurological
proliferation
NSCs
SVZ,
migration
neuroblasts
along
corpus
callosum,
differentiation
towards
neurons
peri-infarct
zone,
resulting
restored
neural
function.
Moreover,
we
revealed
that
NBP-induced
associated
activation
pathway,
which
reversed
DKK1.
In
addition,
increased
production
VEGF
BDNF.
Our
data
unveiled
potentials
recovery
stroke,
dependent
production.
Thus,
be
candidate
for
delayed
treatment
Perm Medical Journal,
Journal Year:
2024,
Volume and Issue:
41(6), P. 92 - 108
Published: Dec. 15, 2024
To
determine
contemporary
prospects
for
the
use
of
non-glycemic
effects
sodium-glucose
cotransporter-2
inhibitors
in
comorbid
patients,
analysis
existing
studies
was
carried
out.
The
mechanisms
action
discovered
during
EMPA-REG
OUTCOME
study
which
were
previously
unknown,
encouraged
further
research
on
these
drugs
other
pathological
conditions.
authors
article
have
analyzed
some
clinical
and
preclinical
this
drug
group
such
conditions
as
stroke,
cancer,
rheumatological
diseases,
rhythm
disorders,
well
their
impact
development
major
adverse
cardiovascular
events.
oxidative
stress
suppression
myocardium
nervous
tissue
with
an
increase
number
mitochondria
reduces
risk
developing
improves
neoangiogenesis
focus
ischemic
necrosis,
has
neuroprotective
are
described
article.
In
oncological
gliflozins
prevent
proliferation
tumor
cells
oncogenesis
through
induction
late
apoptosis
also
cardioprotective
patients
undergoing
chemotherapy.
medicines
incidence
events,
restenosis
after
intravascular
interventions.
positive
effect
course
diseases
improving
laboratory
parameters
a
reducing
frequency
exacerbations
visits
to
doctor
gout.
With
constant
conditions,
it
is
important
carry
out
pleiotropic
subsequent
introduction
new
data
into
practice.
